-
A pooled analysis of three trials of inclisiran in patients with atherosclerotic cardiovascular disease or its risk equivalent showed impressive reductions in LDL cholesterol with subcutaneous injections.
-
ST-elevation myocardial infarction patients without standard risk factors recorded a higher all-cause mortality rate that was particularly evident in women. Using proper therapy in these patients may attenuate this risk.
-
The authors applied an automated algorithm to calculate an Agatston coronary artery calcium score from non-ECG-gated planning CT scans in breast cancer patients undergoing radiation therapy. This provided a graded risk calculation that could encourage preventive measures in patients at highest risk of a cardiovascular disease event.
-
In this study of patients presenting with ST-elevation myocardial infarction and multivessel disease, nonculprit vessel percutaneous coronary intervention (PCI) guided by fractional flow reserve failed to show benefit vs. angiography-guided PCI in terms of clinical events at one year.
-
A recent study of patients who had undergone a percutaneous coronary intervention and were transitioning from dual antiplatelet therapy to monotherapy showed clopidogrel was superior to aspirin for preventing further major adverse events, including bleeding.
-
Among patients with newly diagnosed atrial fibrillation age 66-74 years without other CHA2DS2-VASc risk factors for thromboembolism, the older they are in this age range, the more likely they are to experience a stroke.
-
By adding dapagliflozin to maximally tolerated standard therapy for heart failure with reduced left ventricular ejection fraction, researchers noted the reduction in mortality and recurrent heart failure began within one month of starting this therapy.
-
Almost 40% of acute myocardial infarction malpractice claims result in payment, a higher percentage than any other condition, according to the results of a recent analysis.
-
Does the rhythm in the figure represent Mobitz II second-degree AV block, complete AV block, or Wenckebach? Does the patient need a pacemaker?
-
Dapagliflozin can be prescribed to lower the risk of hospitalization for heart failure in adults with chronic kidney disease at risk for progression, end-stage kidney disease, cardiovascular death, and sustained estimated glomerular filtration rate decline.
